
Amphista Therapeutics have appointed Beverley Carr Chief Business Officer. Amphista is a leader in next generation targeted protein degradation (TPD) …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK

